Source - Alliance News

Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers - Issued a proprietary laboratory code by the American Medical Association’s Current Procedural Terminology Editorial Board. The code was issued for the EpiSwitch Checkpoint-inhibitor Response Test, a test which predicts a patient’s likely response to immune checkpoint inhibitor therapy.

‘Assignment of this unique code is a critical step in the reimbursement process. This code will be effective on October 1 for all requests for insurance reimbursement, whether from Medicare, Medicaid or private payors,’ said Chief Operating Officer Thomas Guiel.

Current stock price: 13.94 pence, up 2.1% on Tuesday in London

12-month change: down 75%

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Oxford Biodynamics PLC (OBD)

-0.09p (-0.95%)
delayed 17:30PM